EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, DaVita's enterprise value is R$124,459 Mil.
DaVita's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was R$60,354 Mil. Therefore, DaVita's EV-to-Revenue for today is 2.06.
The historical rank and industry rank for DaVita's EV-to-Revenue or its related term are showing as below:
BSP:DVAI34'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.58 Med: 1.94 Max: 2.47
Current: 1.79
During the past 13 years, the highest EV-to-Revenue of DaVita was 2.47. The lowest was 1.58. And the median was 1.94.
BSP:DVAI34's EV-to-Revenue is ranked worse than 50.68% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 1.77
vs BSP:DVAI34: 1.79
As of today (2024-04-19), DaVita's stock price is R$680.05.
DaVita's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was R$647.74. Therefore, DaVita's PS Ratio for today is 1.05.
DaVita EV-to-Revenue Historical Data
The historical data trend for DaVita's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
DaVita Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
1.83
2.19
2.08
1.70
1.79
DaVita Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
1.70
1.72
1.87
1.76
1.79
Competitive Comparison
For the Medical Care Facilities subindustry, DaVita's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita EV-to-Revenue Distribution
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where DaVita's EV-to-Revenue falls into.
DaVita's current Enterprise Value is R$124,459 Mil.
DaVita's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$60,354 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita's share price for today is R$680.05.
DaVita's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$647.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of DaVita's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BSP:DVAI34 has been successfully added to your 